Filing Flows

Filing Flows › Health Care › Cue Biopharma (CUE)

Cue Biopharma (CUE) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Cue Biopharma (CUE) Q2 2026 earnings results →

Q2 2026 Revenue up 167% year over year to $7.9M

Cue Biopharma made $7.9M in Q2 2026 (+167% Y/Y). Operating margin n/m, net loss $153M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.

Revenue$7.9M
Year over year+167%
Operating marginn/m
Net earnings−$153M
Operating cash flow−$29.0M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $7.9M in Q2 2026, up 167% year over year and up 39% from the previous quarter.

Operating costs exceeded revenue by $87.7M, an operating margin of -1113.3%. Total costs grew 725% against revenue growth of 167%. The fastest-growing cost line was General & admin (+1166%). The quarter ended with a net loss of $153.1M, wider than the previous quarter's $5.2M loss.

Operating cash flow was −$29.0M. Non-cash charges added back $36K of depreciation and amortization and $23.8M of share-based compensation. Working capital and other items added $100.2M.

Quarterly history

Cue Biopharma revenue by quarterCue Biopharma revenue by quarter$1.6MQ4 2024$421KQ1 2025$3.0MQ2 2025$2.1MQ3 2025$21.9MQ4 2025$5.7MQ1 2026$7.9MQ2 2026
Cue Biopharma net earnings by quarterCue Biopharma net earnings by quarter−$9.5MQ4 2024−$12.3MQ1 2025−$8.5MQ2 2025−$7.4MQ3 2025$1.6MQ4 2025−$5.2MQ1 2026−$153MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 14, 2026$7.9M+167%n/m−$153M−$29.0M
Q1 202610-QMay 14, 2026$5.7M14×-94.1%−$5.2M−$10.9M
Q4 202510-KMar 16, 2026$21.9M14×9.0%$1.6M−$1.1M
Q3 202510-QNov 12, 2025$2.1M-36%-353.4%−$7.4M−$9.0M
Q2 202510-QAug 12, 2025$3.0M+11%-292.3%−$8.5M−$3.4M
Q1 202510-QMay 12, 2025$421K-76%n/m−$12.3M−$8.2M
Q4 202410-KMar 31, 2025$1.6M-14%-611.2%−$9.5M−$9.0M

Charts

Cue Biopharma: revenue growth, year over year and quarter over quarterCue Biopharma: revenue growth, year over year and quarter over quarterY/YQ/Q-14%Q4 2024-76%-73%Q1 2025+11%+400%Q2 2025-36%-27%Q3 2025+400%+400%Q4 2025+400%-74%Q1 2026+167%+39%Q2 2026
Latest (Q2 2026): Y/Y +167%, Q/Q +39%.
Cue Biopharma: where the cash came from (+) and went (−), TTM to Q2 2026Cue Biopharma: where the cash came from (+) and went (−), TTM to Q2 2026Operating cash flow−$50.0MShares issued$37.8MCash drawn (+) / kept (−)$10.1MOther financing$2.0MOther investing$252KCapital spending−$121K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Cue Biopharma: profit against cash, quarter by quarterCue Biopharma: profit against cash, quarter by quarterNet incomeOperating cash flow−$8.7M−$7.5MQ3 2024−$9.5M−$9.0MQ4 2024−$12.3M−$8.2MQ1 2025−$8.5M−$3.4MQ2 2025−$7.4M−$9.0MQ3 2025$1.6M−$1.1MQ4 2025−$5.2M−$10.9MQ1 2026−$153M−$29.0MQ2 2026
Latest (Q2 2026): Net income −$153M, Operating cash flow −$29.0M.
Cue Biopharma: diluted shares by fiscal yearCue Biopharma: diluted shares by fiscal year29MFY202031MFY202136MFY202246MFY202356MFY202495MFY2025
+230.2% since FY2020: more shares outstanding (issuance, stock pay).
Cue Biopharma in its industry: growth against margin (225 companies, SIC 2834)Cue Biopharma in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMCUE (+167%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Cue Biopharma

We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. Unlike conventional approaches that broadly activate the immune system, our Immuno-STAT® platform is designed to selectively modulate disease-relevant T cells, enhancing efficacy while minimizing off-target effects. We believe our Immuno-STAT platform holds the promise of producing drug product candidates with the potential of establishing new standards of care in the treatment of autoimmune and inflammatory diseases. Our programs include, but are not limited to, drug product candidates designed to:

In its own words, from its 10-K, filed Mar 16, 2026.

Cue Biopharma against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +167% against the peers' median +10%.

CompanyQuarterRevenueY/YOp. margin
CUE Cue BiopharmaQ2 2026$7.9M+167%n/m
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Cue Biopharma 10-Q on SEC EDGAR · CIK 1645460 · Pharmaceutical Preparations

13F: who owns CUE and who is buying

Largest holders of CUE (13F)Largest holders of CUE (13F)Bleichroeder LP$11.7MDriehaus Capital Management LLC$9.2MVanguard Capital Management LLC$5.1MIkarian Capital, LLC$3.3MTFG Asset Management GP$3.0MStempoint Capital LP$2.1MBlackRock$1.8MADAR1 Capital Management, LLC$1.7MLion Point Capital, LP$1.7MSquadron Capital Management LLC$1.6M
Funds' net buying of CUE by quarter (13F)Funds' net buying of CUE by quarter (13F)$3912026-03$52.2M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on CUE

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare CUE with

中文版：Cue Biopharma（CUE）财报

Español · Français